12:00 AM
 | 
Feb 18, 2016
 |  BC Innovations  |  Emerging Company Profile

A need for speed

twoXAR's aims to slash lead prioritization time with disease-mapping algorithm

Bioinformatics play twoXAR Inc. aims to condense years of wet-lab compound discovery and lead prioritization into minutes. The company has created an in silico platform that uses machine learning to build a mathematical disease model and predict the efficacy of compounds in that disease.

twoXAR's computational platform, DUMA, is based on CEO Andrew A. Radin's work in biomedical informatics at Stanford University and serves as a drug discovery tool internally, to identify compounds the company could out-license, as well as a system for screening, prioritizing and validating the work of external collaborators.

According to Radin, the company applies DUMA to multiple steps of the discovery process: first, DUMA identifies disease signals from a variety of biological data sets. Then, it builds networks of protein-protein and protein-compound interactions from those data sets to generate a computational disease model that contains interactions between compounds and putative...

Read the full 710 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >